Aprea Therapeutics, Inc. reports developments as a clinical-stage precision medicine oncology company developing targeted therapies for patients with biomarker-defined cancers. Its updates center on small-molecule programs designed to exploit cancer-specific genetic vulnerabilities, including APR-1051, an oral WEE1 kinase inhibitor, and ATRN-119, a small-molecule ATR inhibitor, for solid tumor indications.
Recurring news themes include clinical activity from the ACESOT-1051 study of APR-1051, oncology conference presentations, pipeline and corporate updates, financial results, and financing activity supporting research and development. Company communications also describe biomarker-guided development, safety and tolerability observations, and capital actions tied to its clinical-stage oncology strategy.
Aprea Therapeutics (APRE) will host a virtual panel on WEE1 inhibition in precision oncology on October 20, 2026. The discussion starts at 11 am ET, ahead of the ESMO Congress 2026, and will cover WEE1 biology, drug selectivity challenges and scientific, clinical and market perspectives. Solomon Wilcots will moderate, with participants Alex Spira, Kevin DeGeeter and Aprea Chief Medical Advisor Eugene Kennedy.
Aprea Therapeutics (APRE) announced that President and CEO Oren Gilad will participate in two October 2026 conferences. His Maxim Growth Summit fireside chat is scheduled for October 14 at 9am ET at the Hard Rock Hotel in New York City. The Regional Biotechnology Conference features panel discussions on October 15, from 9am to noon ET, at the Pennsylvania Biotechnology Center in Doylestown, Pennsylvania.
Aprea Therapeutics (APRE) will present updated interim Phase 1 data from the ongoing ACESOT-1051 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors in an oral plenary session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, taking place November 18-20, 2026.
The presentation, titled “Interim results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)”, is scheduled for Friday, November 20, 2026, from 3:00 PM to 3:10 PM CET in Room 111 + 112 at the CCIB. The presenting author will be Timothy A. Yap, MBBS, PhD, FRCP, of the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center and an investigator in the ACESOT-1051 study. Additional information on ACESOT-1051 is available under identifier NCT06260514 on ClinicalTrials.gov.
Aprea Therapeutics (APRE) will present at the H.C. Wainwright 28th Annual Global Investment Conference, held in person and virtually from September 14-16, 2026.
President and CEO Oren Gilad, Ph.D., will deliver the presentation. A webcast link will be available from 4:30 p.m. ET on Monday, September 14, 2026. Investors can register for the conference and may request one-on-one meetings with Aprea management through their H.C. Wainwright representative.
Aprea Therapeutics (Nasdaq: APRE) reported expansion of its global intellectual property portfolio, with 28 issued and 30 pending patents across its precision oncology programs. The WEE1 kinase inhibitor portfolio includes multiple U.S. and international applications and granted patents, with potential patent terms extending to 2047. Lead WEE1 inhibitor APR-1051 is in the ACESOT-1051 Phase 1 trial for advanced/metastatic solid tumors with specific gene alterations.
Aprea’s ATR inhibitor program, including ATRN-119, is protected by four granted U.S. patents, extensive non-U.S. coverage, and pending applications that could extend exclusivity to 2045, plus possible regulatory exclusivities. The ABOYA-119 Phase 1/2a study set an RP2D of 1,100 mg once daily before being closed to prioritize APR-1051, while combination-development options for ATRN-119 are being evaluated.
Aprea Therapeutics (Nasdaq: APRE) reported second quarter 2026 results and pipeline updates, highlighting progress for lead WEE1 inhibitor APR-1051. Enrollment in the Phase 1 ACESOT-1051 trial is accelerating as dose escalation advances, with clinical sites expanding from three to ten and enrollment expected to reach 6–10 patients per month by Q4 2026.
Supported by a $30 million private placement completed in Q1 2026, Aprea plans to enroll at least 50 patients with uterine serous carcinoma or Cyclin E–overexpressing platinum-resistant ovarian cancer and anticipates completing dose escalation and backfill expansion in Q2 2027. Updated Phase 1 data presented at ASCO 2026 showed early single-agent activity and manageable tolerability for APR-1051. Cash and cash equivalents were $41.2 million as of June 30, 2026, which Aprea believes will fund operations into Q1 2028. Q2 2026 operating loss was $4.0 million, with a net loss of $3.6 million or $(0.07) per basic share.
Lipocine (NASDAQ: LPCN) appointed Michael J. Grissinger to its Board of Directors, effective August 3, 2026. The company develops therapeutics using a proprietary oral delivery technology platform.
Grissinger previously spent over two decades at Johnson & Johnson in senior roles leading worldwide pharmaceutical licensing, corporate development, and M&A, including heading Immunology business development and licensing. Earlier, he worked 12 years at Ciba-Geigy in finance, marketing, and business development. He currently serves on the boards of Aprea Therapeutics (Nasdaq: APRE) and Adicet Bio (Nasdaq: ACET), and advises several private biotech companies. According to Lipocine, his experience is expected to support advancement of its pipeline and partnership efforts.
Aprea Therapeutics (Nasdaq: APRE) provided a program update on its oral WEE1 inhibitor APR-1051 from the ongoing Phase 1 dose-escalation ACESOT-1051 trial. The next clinical data update is planned for a medical meeting in Q4 2026, following earlier observations of single-agent activity and a favorable tolerability profile in difficult-to-treat cancers.
According to Aprea, enrollment in ACESOT-1051 is accelerating, with active clinical sites increasing from three to ten and expected enrollment of 6–10 patients per month by Q4 2026. The company is expanding enrollment to include at least 50 patients with uterine serous carcinoma or Cyclin E–overexpressing platinum-resistant ovarian cancer, and anticipates completing dose escalation and backfill expansion in Q2 2027.
Aprea also plans new combination regimens, adding arms in HPV-positive head and neck squamous cell carcinoma (with immune checkpoint therapy) and colorectal cancer (with standard chemotherapy), using dose levels that have cleared safety review and shown single-agent activity, supported by preclinical antitumor and synergy data.
Aprea Therapeutics (Nasdaq: APRE) presented updated Phase 1 data for oral WEE1 inhibitor APR-1051 at ASCO 2026, showing early monotherapy activity and manageable tolerability in advanced solid tumors.
The ACESOT-1051 study reported partial responses, stable disease, dose-proportional PK and ongoing expansion into uterine serous carcinoma and platinum-resistant ovarian cancer, with dose escalation and backfill completion expected in Q2 2027.
Aprea Therapeutics (Nasdaq: APRE) reported first quarter 2026 results and a corporate update. An oversubscribed $30 million private placement closed March 31, boosting cash and cash equivalents to $46.5 million and extending the anticipated cash runway into Q1 2028.
In Phase 1 trial ACESOT-1051 of WEE1 inhibitor APR-1051, 2 partial responses and 6 stable disease cases have been observed among 28 treated patients, with favorable tolerability. Aprea plans to expand enrollment to at least 50 uterine serous carcinoma patients and additional ovarian cancer patients.
ATR inhibitor ATRN-119 in trial ABOYA-119 was paused as Aprea evaluates combination strategies. Q1 2026 operating loss was $3.4 million and net loss was $3.3 million ($0.22 per share), both improved versus Q1 2025.